Eli Lilly Bets $2.25B on Profluent's AI-Designed Gene Editors in 'Beyond CRISPR' Pact
Lilly is paying up to $2.25B in milestones for AI-designed recombinases that can insert entire genes at precise sites — a kilobase-scale alternative to CRISPR that Profluent’s CEO calls the “holy grail” of genetic medicine.
Eli Lilly on April 28 unveiled a multi-program research collaboration with Profluent, the AI-driven biotech company backed by Jeff Bezos, to develop and commercialize AI-designed site-specific recombinases for genetic medicine. Lilly will pay an undisclosed upfront sum plus committed R&D funding, with up to $2.25 billion in development and commercial milestones on the table if every program reaches market, plus tiered royalties on net sales.
The technology pitch is what makes the deal interesting. CRISPR systems are good at cutting DNA, but inserting long, intact genes at precise locations — what Profluent calls kilobase-scale editing — has remained one of the hardest problems in genetic medicine. Recombinases are enzymes that can paste large DNA payloads into specified genomic addresses, but naturally occurring versions are picky about where they’ll work. Profluent’s approach uses generative AI to design custom recombinases programmed to target exact locations in the human genome, dramatically expanding the set of diseases that large-payload gene editing could address. CEO and co-founder Ali Madani called kilobase-scale DNA editing “the holy grail in genetic medicine.”
For Lilly, the deal extends a clear strategic bet. The pharma giant — flush with record revenues from its obesity and diabetes franchises — has spent the past two years buying its way into next-generation genetic medicine, opening a dedicated genetic medicine center in Boston and stacking acquisitions and partnerships across the gene-therapy stack. The Profluent pact is Lilly’s second major recombinase deal in months, following a $1.12 billion collaboration signed with Seamless Therapeutics in January 2026. Together, the two deals signal that Lilly views recombinase-based, large-payload gene editing as a credible successor architecture to CRISPR, not just an adjacent tool.
The collaboration targets diseases with “severe unmet needs” — deal language that typically points at rare and severe genetic conditions where multiple causal mutations cluster and conventional gene therapies struggle. Lilly will hold exclusive rights to advance selected recombinases through development to commercialization. Specific disease focuses, the number of programs covered, and timelines for clinical entry were not disclosed; one industry trade publication described the agreement as “sparse on details,” consistent with early-stage research collaborations where targets shift as designs progress.
The deal also lands as AI-designed biology is having a moment in pharma dealmaking. Profluent built its reputation training large protein language models on the universe of known enzyme sequences, then generating novel proteins with desired properties — a workflow that has produced not just recombinases but also designer Cas-style nucleases and antibody scaffolds. With Lilly’s capital and clinical engine on top of Profluent’s generative pipeline, the partnership is one of the cleanest tests yet of whether AI-designed biology can carry a product all the way to patients.
